Mixed results for etrolizumab in UC trial program

Etrolizumab, an investigational drug developed by Genentech, failed to meet the primary maintenance endpoints in several phase 3 trials and had mixed results in other induction studies, according to a company press release.Researchers evaluated the drug, a dual anti-integrin that inhibits alpha4beta7 and alphaEbeta7, in a trial program comprising eight randomized-controlled trials, as well as two open-label extension and safety monitoring studies.In the studies that explored the drug’s efficacy in inducing remission in patients with moderate to severe ulcerative colitis, etrolizumab metRead More

Share on facebook
Share on twitter
Share on linkedin